Efficient Targeting of T Cell Malignancies In Vitro and In Vivo Using CD4-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells

被引：0
|
作者：
Pinz, Kevin G. [1 ]
Yakaboski, Elizabeth [1 ]
Jares, Alexander [2 ]
Liu, Hua [2 ]
Firor, Amelia E. [1 ]
Wada, Masayuki [1 ]
Leung, Lai-Han [3 ]
Jiang, Xun [1 ]
Ma, Yupo [2 ]
机构：
[1] ICell Gene Therapeut LLC, Stony Brook, NY USA
[2] Stony Brook Med, Pathol, Stony Brook, NY USA
[3] Macau Univ Sci & Technol, Inst Appl Res Med, Macau, Peoples R China
来源：
MOLECULAR THERAPY | 2016年 / 24卷
关键词：
D O I：
10.1016/S1525-0016(16)33455-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
647
引用
收藏
页码：S256 / S257
页数：2
相关论文
共 50 条
  • [31] Adapter Chimeric Antigen Receptor (ADCAR)-Engineered NK-92 Cells Targeting Neuroblastoma
    Buchner, M.
    Grote, S.
    Jung, G.
    Baden, C.
    Mittelstaet, J.
    Kaiser, A.
    Handgretinger, R.
    Schleicher, S.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S425 - S426
  • [32] Chimeric antigen receptor T cells for gamma–delta T cell malignancies
    P. A. Wawrzyniecka
    L. Ibrahim
    G. Gritti
    M. A. Pule
    P. M. Maciocia
    Leukemia, 2022, 36 : 577 - 579
  • [33] At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies
    Daniyan, Anthony F. O.
    Brentjens, Renier J.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 100 (06) : 1255 - 1264
  • [34] Chimeric Antigen-Receptor (CAR)-Engineered Natural Killer (NK) Cells Targeting Chronic Myeloid Leukemia (CML) Blast Crisis
    Imeri, Jusuf
    Marcoux, Paul
    Huyghe, Matthias
    Desterke, Christophe
    Fantacini, Daianne
    Griscelli, Frank
    Covas, Dimas T.
    Botelho de Souza, Lucas Edouardo
    Griscelli, Annelise Bennaceur
    Turhan, Ali
    BLOOD, 2023, 142
  • [35] Development and in vivo evaluation of anti-CD19 chimeric antigen receptor (CAR) -yδt cells
    Kim, Nayoung
    Kim, Hyery
    Im, Ho Joon
    Koh, Kyung-Nam
    TISSUE ENGINEERING PART A, 2022, 28 : 278 - 278
  • [36] PiggyBac, an Efficient Method for Genetic Modification of T Cells with Second Generation CD19-Specific Chimeric Antigen Receptor (CAR) for Treatment of B-Lineage Malignancies
    Manuri, Pallavi R.
    Maiti, Sourindra N.
    Singh, Harjeet
    Mi, Tiejuan
    Olivares, Simon
    Dawson, Margaret J.
    Huls, Helen
    Lee, Dean A.
    Rao, Pulivarthi H.
    Kaminski, Joseph M.
    Kebriaei, Partow
    Wilson, Matthew H.
    Cooper, Laurence J. N.
    MOLECULAR THERAPY, 2009, 17 : S212 - S213
  • [37] Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
    Esmaeilzadeh, Abdolreza
    Hadiloo, Kaveh
    Jabbari, Marjan
    Elahi, Reza
    LIFE SCIENCES, 2024, 337
  • [38] FGFR4 specific chimeric antigen receptor (CAR) T cell therapy against rhabdomyosarcoma
    Shivaprasad, Nityashree
    Yohe, Marielle
    Xiong, Ying
    Wu, Darong
    Azorsa, Peter
    Cheuck, Adam
    Chung, Joon-Yong
    Zhu, Zhongyu
    Dimitrov, Dimiter
    Hewitt, Stephen
    Dropulic, Boro
    Schneider, Dina
    Orentas, Rimas
    Khan, Javed
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [39] At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies
    Oluwole, Olalekan O.
    Davila, Marco L.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 100 (06) : 1265 - 1272
  • [40] Chimeric antigen receptor T cells for gamma-delta T cell malignancies
    Wawrzyniecka, P. A.
    Ibrahim, L.
    Gritti, G.
    Pule, M. A.
    Maciocia, P. M.
    LEUKEMIA, 2022, 36 (02) : 577 - 579
12345